Lenzing AG: B&C Group and Suzano Enter Into Long-term Partnership
B&C Group (“B&C”) and Suzano S.A. (“Suzano”) today announce that Suzano has entered into a long-term partnership with B&C with respect to its majority stake in Lenzing AG (“Lenzing” or “the company”), the Vienna-listed leading global supplier of cellulosic fibres for the textile and non-wovens industry.
Under the terms of the agreement, Suzano will acquire a 15 percent stake in Lenzing from B&C and the two shareholders will form a long-term syndicate which will hold the majority stake (52.25 percent) in the company. Subject to the closing of the transaction, B&C will hold a 37.25 percent stake in Lenzing and keep the role as controlling member of the new syndicate, with Suzano holding the minority stake of 15 percent. The price per share will be EUR 39.70, with a total acquisition purchase price of EUR 230 million to be fully paid at closing.
As part of the long-term partnership, Suzano has the option to acquire an additional 15 percent stake in the company from B&C until the end of 2028. The agreement also stipulates that B&C will remain a committed long-term shareholder in the company.
With an annual net revenue of more than EUR seven billion in 2023, Brazil-headquartered Suzano is the world’s largest market pulp producer. The company, which is celebrating its centennial year, has a long-standing track record of both operational excellence and commitment to sustainability at all stages of its processes, expertise that will complement Lenzing’s existing business model. Suzano is no direct competitor of Lenzing and has extensive experience in pulp, a raw material with significant importance for Lenzing.
Moving forward, B&C and Suzano plan to support Lenzing’s further development by focusing on driving revenue growth, improving profitability and expanding the company’s international competitiveness.
Walter Schalka, CEO of Suzano, said: “Lenzing is already a leading global supplier of premium cellulosic fibres for the textile and non-wovens industry and we recognize opportunities exist for further growth with its established technology, product range and technical knowledge. Our deep-rooted understanding of pulp production and cost excellence makes Suzano, alongside B&C, an ideal partner for Lenzing as it seeks strengthening its competitive position and global presence. For us, this represents a continuation of our strategy focused on investments which enlarge our addressable market in scalable and competitive business models and move us closer to the end-consumer.”
Wolfgang Hofer, Chairman of B&C Group: “We see this partnership as a win-win-win situation for each party involved. With Suzano, B&C will add a financially strong key shareholder for Lenzing with extensive experience and strong reputation on the international financial markets. Suzano as the leading global pulp producer gains proximity to new markets thanks to this transaction. For Lenzing, this transaction means a commitment of both partners to strengthen Lenzing’s position as a global market leader for sustainable cellulosic fibres.”
In line with the foundation purpose of B&C Private Foundation, the new partners have agreed on a long-term commitment to the existing Lenzing site which will ensure the company’s headquarters, production facilities and key R&D activities remain located in Austria. The partnership also guarantees the continued listing of Lenzing shares on the Vienna stock exchange.
The transaction is subject to approval by the relevant regulatory authorities.
About Suzano S.A.
Suzano is the world’s largest producer of market pulp. Our responsibly grown raw materials are used in products reaching over two billion people in more than 100 countries, including tissue and toilet paper, books, printing and writing paper, diapers and period products, packaging, textiles, and a range of innovative applications that can replace products made from fossil fuels.
Our pulp is made using biomass produced from farmed eucalyptus trees, offering a biodegradable, renewable and recyclable raw material for consumer and industrial use. We plant 1.2 million trees a day on our farms and only harvest what we plant. We manage around 26,000 km2 of land and around 40% of this is protected for permanent conservation, with a zero-deforestation policy across all of our operations.
Suzano’s history goes back over 100 years. We are listed on the B3 stock exchange in Brazil (SUZB3) and the NYSE (SUZ) in the United States.
Learn more at: suzano.com.br/en
About B&C Group
The B&C Private Foundation (www.bcprivatstiftung.at) is an independent foundation. Since its inception in December 2000, its goal has been to foster Austrian entrepreneurship and strengthen Austria’s position as a business hub. B&C acts as a stable core shareholder in Austrian industrial companies through its holding companies, the B&C Group (www.bcgruppe.at). B&C is core shareholder of Lenzing AG and holds majority stakes in Semperit AG Holding (54.2%) and AMAG Austria Metall AG (52.7%). Through B&C Innovation Investments, B&C Group has been investing in tech-driven growth companies since 2016. It currently holds stakes in Awake Mobility, Citrine, Contextflow, Flightkeys, Frequentis, Kinexon, Klarx, Neoom, ParityQC, TriLite und TTTech.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240612561637/en/
Contacts
Press Contact:
B&C-Group: Jürgen Gangoly, Spokesperson, Phone: +43 664 2000260, Email:
j.gangoly@bcholding.at
Suzano S.A.: Hawthorn Advisors, Email: suzano@hawthornadvisors.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeiGene Highlights Innovative Hematology Portfolio Across B-cell Malignancies at ASH 20245.11.2024 15:05:00 CET | Press Release
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will share new data across a range of B-cell malignancies and assets, including best-in-class Bruton’s tyrosine kinase (BTK) inhibitor BRUKINSA® (zanubrutinib), at the 66th ASH Annual Meeting and Exposition in San Diego, December 7-10. BeiGene has 21 abstracts accepted at ASH 2024, with four selected for oral presentation. “In the five years since its initial approval, BRUKINSA has become a standard of care for patients facing many B-cell malignancies, and our data featured at ASH demonstrated how long-term follow-up of treatment with BRUKINSA elicited deep and durable responses, including in patients with chronic lymphocytic leukemia and Waldenström’s macroglobulinemia,” said Mehrdad Mobasher, M.D., M.P.H., Chief Medical Officer, Hematology at BeiGene. “BRUKINSA is just the starting point – pipeline data for our BTK degrader BGB-16673 and BCL2 inhibitor sonrotoclax showcase our contin
DirectSens’ Market-Leading LactoSens ® Biosensor Technology Acquired by Kerry Group P.L.C.5.11.2024 14:00:00 CET | Press Release
DirectSens, a pioneer in next generation biosensor technology, announces the acquisition of its LactoSens® technology by Kerry Group, a global leader in taste and nutrition. The acquisition of LactoSens® reflects DirectSens’ success in developing end-to-end biosensor solutions and represents a move by Kerry Group to complement its offering in lactase enzymes. As an indispensable analytical tool, LactoSens® will work alongside Kerry Group’s ingredient solutions, enabling a more integrated offering for food manufacturers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241105399369/en/ LactoSens®, Industry Gold Standard Biosensor Kit. Developed and manufactured by DirectSens in Vienna, AUSTRIA, © DirectSens GmbH 2024 “We’re excited to bring LactoSens® into Kerry Group’s portfolio to add a new element to our offering, as we fully integrate LactoSens® into our broader solutions for the food and beverage industry.” — Ronan Moloney
Technology Holdings Has Expanded Operations into Brazil, Driving Growth in Latin America5.11.2024 13:35:00 CET | Press Release
Technology Holdings (TH), an award-winning global boutique investment bank with a track record of closing transactions in 24 countries, proudly announces its strategic expansion into Brazil, leveraging digital transformation within one of Latin America’s largest economies. This move significantly strengthens Technology Holdings’ presence in the rapidly growing Latin American market, enabling the firm to play a vital role in the region's expanding M&A landscape. According to Dealogic, M&A deals totaling $35 billion have been announced, reflecting a 56% increase compared to the same period last year. As companies increasingly look to consolidate and expand, Technology Holdings is uniquely positioned to provide strategic guidance and facilitate successful transactions. “The expansion into Brazil represents an exciting opportunity for us to deepen our relationships within this vibrant market,” said Edoardo Freschet, Head of Latin America at Technology Holdings. “The quality of talent and t
EUMETSAT: Lisbon Event Offers a Deep Dive Into Ocean Data5.11.2024 13:07:00 CET | Press Release
People with an interest in our oceans – from academics to businesspeople through to representatives from navies and weather services – are meeting in Lisbon, Portugal, for a deep dive into satellite data and its uses. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241105106009/en/ (Photo: Business Wire) Europe’s meteorological satellite agency, EUMETSAT, the European Commission, the European Space Agency, the European Centre for Medium-Range Weather Forecasts and Mercator Ocean International are hosting the two-day event starting today. The aim is to showcase how data from the Copernicus Sentinel satellites are used to benefit agencies and businesses with an interest in the marine environment, to connect data users with different skills and expertise, and to receive feedback on how to better meet the needs of existing and potential data users. “What happens in our oceans influences everyone’s lives by impacting our weather,
Delta-Fly Pharma Inc.: Update for Expanded Phase I Study of DFP-149275.11.2024 12:00:00 CET | Press Release
We are excited to share our latest development status. As informed dated October 28th, an interim analysis for the Phase III study ofDFP-10917 in R/R AML patients is ongoing. The Phase I/II combination study of DFP-10917 with Venetoclax in AML patients is well ongoing. Today, we are delighted to talk about an update for development of the drug delivery of DFP-10917 selective to solid tumor, which is namely, DFP-14927 showed nice safety and efficacy in the Phase I study in solid tumor patients. Accordingly, we have moved forward into an expanded Phase I study of DFP-14927 at 3200 mg/m2 weekly dosing in R/R colorectal cancer patients at MD Anderson Cancer Center and UCLA. Efficacy in expanded Phase I study is evaluated by Disease Control Ratio (DCR) and it shall be evaluated by OS in the next registration study for NDA approval. View source version on businesswire.com: https://www.businesswire.com/news/home/20241105884234/en/
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom